


Customer Number



Patent  
Case No.: 59068US002

If u

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/714053

Group Art Unit: 1614

Filed: November 14, 2003

Examiner: Unknown

Title: N-SULFONYLDICARBOXIMIDE CONTAINING TETHERING COMPOUNDS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]**


I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 872-9306.

**APR 11 2005**

Date \_\_\_\_\_



Signed by: Lydia M. Cahill

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

Under 37 CFR § 1.97(e)(1), I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Respectfully submitted,

April 1, 2005  
Date


By: Jean A Lown  
Jean A. Lown, Reg. No.: 48,428  
Telephone No.: (651) 733-3169

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: 651-736-3833

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 1 of 1



Application Number	10/714053
Filing Date	November 14, 2003
First Named Inventor	Benson, Karl E.
Art Unit	1614
Examiner Name	Unknown
Attorney Case Number	59068US002

## U.S. Patent Documents

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US- 5238950	08/24/1993	Clader et al.	
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			
	A9	US-			
	A10	US-			
	A11	US-			

## Foreign Patent Documents

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1	JP	53 063375	06/06/1978			Abstract
	B2	PCT	WO02/094890	11/28/2002			
	B3	PCT	WO03/068712	08/21/2003			
	B4	PCT	WO2004/067732	08/12/2004			

## OTHER DOCUMENTS

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Database Caplus"Online! Chemical Abstracts Service, Columbus, Ohio, US; Lukovits, Istvan: "Decomposition of Wiener Topological Index. Application to Drug-receptor Interactions" XP002321504	
	C2		
	C3		

\*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.